Related Experiment Video
Updated: Mar 1, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
1.2K
Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis
Lichao Fan1,2, Xiaoting Yu1, Ziling Huang1
1Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
Mediators of Inflammation
|June 8, 2017
Summary
Researchers identified 45 differentially expressed microRNAs and 67 genes linked to idiopathic pulmonary fibrosis (IPF) using bioinformatics. These findings may lead to new biomarkers for predicting IPF progression.
Area of Science:
- Genomics
- Bioinformatics
- Molecular Biology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options.
- Identifying molecular markers is crucial for understanding IPF pathogenesis and progression.
Purpose of the Study:
- To identify novel microRNAs (miRNAs) and genes associated with IPF using publicly available microarray data.
- To explore potential miRNA-gene interactions and construct a regulatory network for IPF.
Main Methods:
- Downloaded miRNA (GSE32538) and mRNA (GSE32537, GSE53845, GSE10667) datasets from the Gene Expression Omnibus (GEO) database.
- Utilized GEO2R for screening differentially expressed miRNAs (DE-miRNAs) and genes (DEGs).
- Performed comprehensive bioinformatic analyses, including pathway enrichment and miRNA-target prediction using multiple online tools.
Main Results:
- Identified 45 DE-miRNAs and 67 common DEGs between IPF and control tissues.
- Functional analysis revealed significant enrichment in cancer and ECM-receptor interaction pathways.
- Predicted potential interactions between 17 DE-miRNAs and 17 DEGs, constructing a miRNA-mediated regulatory network.
Conclusions:
- The study identified key DE-miRNAs and DEGs potentially involved in IPF pathogenesis.
- The constructed regulatory network offers insights into miRNA-gene interactions in IPF.
- These findings may contribute to developing novel biomarkers for IPF prediction and management.
